A study of Dato-DXd in Chinese Patients with Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

Trial Identifier: D9266C00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo, Inc.
Start Date: July 2022
Primary Completion Date: November 2023
Study Completion Date: June 2025
Condition: Lung Cancer; Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version (TNBC Cohort)
Simplified Chinese (TNBC) Translation

Trial Locations

Country Location
CN Beijing, CN, 100142
CN Beijing, CN, 100044
CN Bengbu, CN, 233004
CN Changchun, CN, 130012
CN Changchun, CN, 130021
CN Chengdu, CN, 610000
CN Chongqing, CN, 400030
CN Dalian, CN, 116023
CN Fuzhou, CN, 350001
CN Guangzhou, CN, 510100
CN Guangzhou, CN, 510060
CN Hangzhou, CN, 310022
CN Harbin, CN, 150081
CN Jinan, CN, 250030
CN Jinan, CN, 250117
CN Nanchang, CN, 330006
CN Nanchang, CN, 330009
CN Shenyang, CN, 110042
CN Wuhan, CN, 430022
CN Wuhan, CN, 430030